Company: RPTX
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0000950170-25-105468
Chunk: 5

Company: Repare Therapeutics Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Item 2
Chunk 5
---
 or Debiopharm, for lunresertib. 

We continue to actively explore a full range of strategic alternatives, partnerships and sale opportunities across our portfolio to maximize shareholder value. 

Our Pipeline 

•RP-3467 - We are conducting a Phase 1 clinical trial of RP-3467 (POLAR), dosing patients alone and in combination with the poly-ADP ribose polymerase (PARP) inhibitor, olaparib. POLAR is a multi-center, open-label, dose-escalation Phase 1 clinical trial designed to investigate the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RP-3467 alone or in combination with olaparib in adults with locally advanced or metastatic epithelial ovarian cancer, metastatic breast cancer, metastatic castration-resistant prostate cancer, or pancreatic adenocarcinoma. 

oUpcoming expected milestone: 

▪Q4-2025 - Topline safety, tolerability and early efficacy data from the POLAR trial in monotherapy and in combination with olaparib.